Patents Assigned to Orth-McNeil Pharmaceutical, Inc.
  • Aza-bridged-bicyclic amino acid derivatives as ?4 integrin antagonists
    Patent number: 6960597
    Abstract: The invention is directed to aza-bridged-bicyclic compounds having Formula (I): and pharmaceutically acceptable salts thereof. The compounds are useful (?4 integrin receptor antagonists and, in particular, ?4?1 and ?4?7 integrin receptor antagonists. The invention is further directed to methods for use of the instant compounds for treating integrin mediated disorders including, but not limited to, inflammatory disorders, autoimmune disorders and cell-proliferative disorders, methods for preparing the compounds and methods for preparing the intermediates, derivatives and pharmaceutical compositions thereof.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: November 1, 2005
    Assignee: Orth-McNeil Pharmaceutical, Inc.
    Inventors: Alexey B. Dyatkin, Bruce E. Maryanoff, William J. Hoekstra, Wei He, William A. Kinney
  • Benzo[4,5]thieno[2,3-c]pyridine and Benzo[4,5]furo[2,3-c]pyridine Derivatives Useful as Inhibitors of Phosphodiesterase
    Patent number: 6864253
    Abstract: The present invention relates to novel ?-carboline derivatives of the general formula wherein all the variables are as described within the specification, useful as phosphodiesterase inhibitors. The present invention further relates to use of the described derivatives for the treatment of diseases and conditions related to PDE, for example male erectile dysfunction.
    Type: Grant
    Filed: October 1, 2002
    Date of Patent: March 8, 2005
    Assignee: Orth-McNeil Pharmaceutical, Inc.
    Inventors: Zhihua Sui, Mark J. Macielag
  • Methods for Identifying modulators of serine protease EOS
    Patent number: 6806059
    Abstract: Here we describe the molecular identification of a cDNA encoding a novel serine protease we have termed protease EOS. The deduced amino acid sequence, and it alignment with other well-characterized serine proteases indicates that it is a member of the S1 serine protease family. We have found that the protease EOS mRNA is expressed in platelets and leukocytes and more specifically eosinophils. Although this protease is abundantly expressed in ovary, retina and stomach, where it may perform important functions, its expression in platelets and certain cells of the immune system suggests that it may play roles in thrombosis and in the immune process.
    Type: Grant
    Filed: January 8, 2002
    Date of Patent: October 19, 2004
    Assignee: Orth-McNeil Pharmaceutical, Inc.
    Inventors: Andrew Darrow, Jenson Qi, Patricia Andrade-Gordon
  • Methods for the synthesis of dioxoalkanoic acid compounds
    Patent number: 6355812
    Abstract: The invention relates to improved methods of producing aryl dioxoalkanoic acid compounds and derivatives useful as intermediates for diarylpyrrole therapeutic agents by the alcoholysis of benzoylcyclohexanone ketal compounds.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: March 12, 2002
    Assignee: Orth-McNeil Pharmaceutical, Inc.
    Inventors: Michael P. Ferro, Kathleen A. McCoy
  • Substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia
    Patent number: 6218396
    Abstract: This invention relates a to a series of heterocyclic substituted piperazines of Formula I methods of treatment, pharmaceutical compositions containing them, and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &agr;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.
    Type: Grant
    Filed: February 18, 1999
    Date of Patent: April 17, 2001
    Assignee: Orth-McNeil Pharmaceutical, Inc.
    Inventors: Gee-Hong Kuo, William V. Murray, Catherine P. Prouty